%	O
%	O
TITLE	O

Stratification	O
of	O
HPV	O
-	O
associated	O
and	O
HPV	O
-	O
negative	O
oropharyngeal	O
squamous	O
cell	O
carcinomas	O
based	O
on	O
DNA	O
methylation	O
epigenotypes	O
.	O

%	O
%	O
ABSTRACT	O

While	O
the	O
incidence	B-Incidence_or_Prevalence
of	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
has	O
been	O
increasing	O
in	O
these	O
two	O
decades	O
,	O
primarily	O
due	O
to	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
,	O
stratification	O
of	O
OPSCC	O
into	O
molecular	O
subgroups	O
showing	O
different	O
clinicopathological	O
features	O
has	O
not	O
been	O
fully	O
investigated	O
.	O

We	O
performed	O
DNA	O
methylome	O
analysis	O
using	O
Infinium	O
450k	O
for	O
170	O
OPSCC	O
cases	O
,	O
including	O
89	O
cases	O
in	O
our	O
cohort	O
and	O
81	O
cases	O
reported	O
by	O
The	O
Cancer	O
Genome	O
Atlas	O
,	O
together	O
with	O
targeted	O
exon	O
sequencing	O
analysis	O
.	O

We	O
stratified	O
OPSCC	O
by	O
hierarchical	O
clustering	O
analysis	O
using	O
methylome	O
data	O
.	O

Methylation	O
levels	O
of	O
classifier	O
markers	O
were	O
validated	O
quantitatively	O
using	O
pyrosequencing	O
,	O
and	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
values	O
of	O
receiver	O
operating	O
characteristics	O
(	O
ROC	O
)	O
curves	O
were	O
calculated	O
.	O

OPSCC	O
was	O
stratified	O
into	O
four	O
epigenotypes	O
:	O
HPV	O
(	O
+	O
)	O
high	O
-	O
methylation	O
(	O
OP1	O
)	O
,	O
HPV	O
(	O
+	O
)	O
intermediate	O
-	O
methylation	O
(	O
OP2	O
)	O
,	O
HPV	O
(	O
-	O
)	O
intermediate	O
-	O
methylation	O
(	O
OP3	O
)	O
and	O
HPV	O
(	O
-	O
)	O
low	O
-	O
methylation	O
(	O
OP4	O
)	O
.	O

Ten	O
methylation	O
marker	O
genes	O
were	O
generated	O
:	O
five	O
to	O
classify	O
HPV	O
(	O
+	O
)	O
cases	O
into	O
OP1	O
and	O
OP2	O
,	O
and	O
five	O
to	O
classify	O
HPV	O
(	O
-	O
)	O
cases	O
into	O
OP3	O
and	O
OP4	O
.	O

AUC	O
values	O
of	O
ROC	O
curves	O
were	O
0	O
.	O
969	O
and	O
0	O
.	O
952	O
for	O
the	O
two	O
marker	O
panels	O
,	O
respectively	O
.	O

While	O
significantly	O
higher	O
TP53	O
mutation	O
and	O
CCND1	O
copy	O
number	O
gains	O
were	O
observed	O
in	O
HPV	O
(	O
-	O
)	O
than	O
in	O
HPV	O
(	O
+	O
)	O
groups	O
(	O
pâ€‰	O
<	O
â€‰0	O
.	O
01	O
)	O
,	O
no	O
significant	O
difference	O
of	O
genomic	O
aberrations	O
was	O
observed	O
between	O
OP1	O
and	O
OP2	O
,	O
or	O
OP3	O
and	O
OP4	O
.	O

The	O
four	O
epigenotypes	O
showed	O
significantly	O
different	O
prognosis	O
(	O
p	O
=	O
0	O
.	O
0006	O
)	O
,	O
distinguishing	O
the	O
most	O
favorable	O
OPSCC	O
subgroup	O
(	O
OP1	O
)	O
among	O
generally	O
favorable	O
HPV	O
(	O
+	O
)	O
cases	O
,	O
and	O
the	O
most	O
unfavorable	O
OPSCC	O
subgroup	O
(	O
OP3	O
)	O
among	O
generally	O
unfavorable	O
HPV	O
(	O
-	O
)	O
cases	O
.	O

HPV	O
(	O
+	O
)	O
and	O
HPV	O
(	O
-	O
)	O
OPSCC	O
are	O
further	O
divided	O
into	O
distinct	O
DNA	O
methylation	O
epigenotypes	O
,	O
showing	O
significantly	O
different	O
prognosis	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Study	O
design	O

We	O
performed	O
DNA	O
methylome	O
analysis	O
using	O
Inﬁnium	O
450k	O
for	O
89	O
OPSCC	O
cases	O
and	O
targeted	O
exon	O
sequencing	O
for	O
86	O
OPSCC	O
cases	O
,	O
and	O
analyzed	O
the	O
data	O
together	O
with	O
81	O
cases	O
reported	O
by	O
TCGA	O
.	O

We	O
stratiﬁed	O
OPSCC	O
by	O
hierarchical	O
clustering	O
analysis	O
using	O
methylome	O
data	O
.	O

Methylation	O
levels	O
of	O
classiﬁer	O
markers	O
were	O
validated	O
quantitatively	O
using	O
pyrosequencing	O
,	O
and	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
values	O
of	O
receiver	O
operating	O
characteristics	O
(	O
ROC	O
)	O
curves	O
were	O
calculated	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S1	O
)	O
.	O

Clinical	O
samples	B-HPV_Sample_Type
and	O
cells	O

Clinical	O
specimens	B-HPV_Sample_Type
were	O
collected	O
from	O
96	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
who	O
underwent	O
therapy	O
at	O
Chiba	O
University	O
Hospital	O
or	O
Hamamatsu	O
University	O
Hospital	O
.	O

Fifty	O
-	O
nine	O
OPSCC	B-HPV_Sample_Type

samples	I-HPV_Sample_Type
were	O
obtained	O
at	O
Chiba	O
University	O
,	O
and	O
37	O
OPSCC	O
samples	B-HPV_Sample_Type
were	O
obtained	O
at	O
Hamamatsu	O
University	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O

Non	O
-	O
cancerous	O
mucosa	O
samples	B-HPV_Sample_Type
were	O
obtained	O
from	O
OPSCC	B-Study_Cohort
patients	I-Study_Cohort
via	O
biopsy	B-HPV_Sample_Type
from	O
the	O
side	O
opposite	O
to	O
the	O
cancerous	O
side	O
.	O

These	O
biopsy	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
were	O
immediately	O
frozen	O
in	O
liq	O
-	O
uid	O
nitrogen	O
and	O
stored	O
at	O
−80oC	O
.	O

The	O
cancer	O
cell	O
content	O
of	O
the	O
frozen	O
materials	O
was	O
determined	O
to	O
be	O
≤10	O
,	O
20	O
,	O
30	O
,	O
40	O
,	O
50	O
,	O
60	O
,	O
70	O
,	O
80	O
or	O
≥90	O
%	O
through	O
microscopic	O
examination	O
by	O
two	O
independent	O
pathologists	O
,	O
and	O
was	O
enriched	O
by	O
dissection	O
when	O
necessary	O
.	O

Among	O
96	O
samples	B-HPV_Sample_Type
,	O
89	O
samples	B-HPV_Sample_Type
,	O
of	O
which	O
the	O
can	O
-	O
cer	O
cell	O
content	O
was	O
determined	O
≥50	O
%	O
by	O
both	O
the	O
two	O
pathol	O
-	O
ogists	O
,	O
were	O
used	O
for	O
subsequent	O
molecular	O
analyses	O
.	O

The	O
remaining	O
seven	O
samples	B-HPV_Sample_Type
were	O
excluded	O
because	O
two	O
con	O
-	O
tained	O
no	O
cancer	O
cell	O
,	O
three	O
were	O
determined	O
as	O
≤50	O
%	O
cancer	O
cell	O
content	O
by	O
both	O
pathologists	O
,	O
and	O
two	O
were	O
determined	O
as	O

≤50	O
%	O
by	O
one	O
pathologist	O
.	O

DNA	O
was	O
extracted	O
using	O
the	O

QIAquick	O
DNA	O
mini	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

DNA	O
of	O
normal	O
peripheral	O
blood	O
cells	O
(	O
PBC	O
)	O
was	O
purchased	O
from	O
the	O
Coriell	O
Cell	O
Repositories	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
at	O
Chiba	O
University	O
and	O
Hamama	O
-	O
tsu	O
University	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique

IHC	B-HPV_Lab_Technique
for	I-HPV_Lab_Technique
p53	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
a	I-HPV_Lab_Technique
DO	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
7	I-HPV_Lab_Technique
anti	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
mouse	I-HPV_Lab_Technique
mono	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
clonal	I-HPV_Lab_Technique
antibody	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
anti	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
p53	I-HPV_Lab_Technique
DO	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
7	I-HPV_Lab_Technique
primary	I-HPV_Lab_Technique
antibody	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Roche	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Basel	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Switzerland	I-HPV_Lab_Technique
)	O
and	O
the	O
BenchMark	O
ULTRA	O
automated	O
staining	O
system	O
(	O
Roche	O
)	O
.	O

Samples	B-HPV_Sample_Type
with	O
diffuse	O
strong	O
positive	O
nuclear	O
staining	O
were	O
considered	O
p53	O
-	O
IHC	O
(	O
+	O
)	O
and	O
designated	O
as	O
TP53	O
-	O
mutation	O
(	O
+	O
)	O
,	O
while	O
those	O
with	O
negative	O
nuclear	O
staining	O
were	O
considered	O
p53	O
-	O
IHC	O
(	O
−	O
)	O
and	O
also	O
designated	O
as	O
TP53	O
-	O
mutation	O
(	O
+	O
)	O
.	O

Those	O
with	O
sporadic	O
positive	O
nuclear	O
staining	O
were	O
considered	O
p53	O
-	O
IHC	O
wild	O
-	O
type	O
and	O
designated	O
as	O
TP53	O
-	O
muta	O
-	O
tion	O
(	O
−	O
)	O
.	O

For	B-HPV_Lab_Technique
p16INK4A	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
an	I-HPV_Lab_Technique
antimouse	I-HPV_Lab_Technique
monoclonal	I-HPV_Lab_Technique
antibody	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
CINtec	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
Histology	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Roche	I-HPV_Lab_Technique
)	O
and	O
BenchMark	O
ULTRA	O
,	O
and	O
samples	B-HPV_Sample_Type
with	O
positive	O
nuclear	O
staining	O
(	O
nuclear	O
and	O
cytoplasmic	O
immunoreactivity	O
in	O
>	O
75	O
%	O
of	O
tumor	O
cells	O
)	O
were	O
considered	O
p16	O
-	O
IHC	O
(	O
+	O
)	O
and	O
designated	O
as	O
p16	O
(	O
+	O
)	O
.	O

Ampliﬁcation	O
of	O
L1	O
DNA	O
region	O
in	O
high	O
-	O
risk	O
HPV	O

HPV	O
infection	O
status	O
was	O
evaluated	O
by	O
amplifying	O
a	O
portion	O
of	O
the	O
L1	O
region	O
in	O
high	O
-	O
risk	O
HPV	O
using	O
GP5	O
and	O
GP6	O
primers	O
,	O
as	O
previously	O
reported	O
.	O
28	O
Samples	O
with	O
the	O
PCR	B-HPV_Lab_Technique
amplicon	O
were	O
designated	O
as	O
HPV	O
-	O
L1	O
(	O
+	O
)	O
.	O

Inﬁnium	O
assays	O

The	O
Inﬁnium	O
HumanMethylation450	O
BeadChip	O
(	O
Illumina	O
)	O
contains	O
approximately	O
485	O
,	O
000	O
individual	O
CpG	O
sites	O
covering	O
99	O
%	O
RefSeq	O
genes	O
with	O
an	O
average	O
of	O
17	O
CpG	O
sites	O
per	O
gene	O
.	O

For	O
each	O
CpG	O
site	O
,	O
β	O
-	O
value	O
,	O
ranging	O
from	O
0	O
.	O
00	O
to	O
1	O
.	O
00	O
,	O
was	O
measured	O
using	O
a	O
methylated	O
probe	O
relative	O
to	O
the	O
sum	O
of	O
both	O
methylated	O
and	O
unmethylated	O
probes	O
.	O

Bisulﬁte	O
conver	O
-	O
sion	O
was	O
performed	O
using	O
the	O
Zymo	O
EZ	O
DNA	O
methylation	O
kit	O
(	O
Zymo	O
Research	O
,	O
Irvine	O
,	O
CA	O
)	O
with	O
500	O
ng	O
of	O
genomic	O
DNA	O

for	O
each	O
sample	O
.	O

Whole	O
genome	O
ampliﬁcation	O
,	O
labeling	O
,	O
hybridization	O
and	O
scanning	O
were	O
performed	O
according	O
to	O
the	O
manufacturer’s	O
protocols	O
.	O

Inﬁnium	O
analysis	O
was	O
performed	O
against	O
89	O
clinical	O
OPSCC	O
and	O
ﬁve	O
noncancerous	O
mucosa	O
samples	B-HPV_Sample_Type
.	O

For	O
analyzing	O
DNA	O
methylation	O
at	O
promoter	O
regions	O
based	O
on	O
Inﬁnium	O
data	O
,	O
the	O
probe	O
nearest	O
to	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
was	O
selected	O
when	O
multiple	O
probes	O
were	O
designed	O
for	O
one	O
promoter	O
region	O
.	O

The	O
CpG	O
score	O
for	O
each	O
probe	O
was	O
calcu	O
-	O
lated	O
based	O
on	O
a	O
previous	O
report	O
.	O
29	O
,	O
30	O
For	O
analysis	O
of	O
CpG	O
island	O
shore	O
regions	O
,	O
N	O
_	O
Shore	O
and	O
S	O
_	O
Shore	O
,	O
the	O
probe	O
nearest	O
to	O
TSS	O
was	O
selected	O
among	O
probes	O
at	O
the	O
CpG	O
island	O
shore	O
(	O
annotated	O
by	O
Illumina	O
)	O
.	O

For	O
analysis	O
of	O
gene	O
body	O
,	O
the	O
probe	O
showing	O
the	O
highest	O
CpG	O
score	O
was	O
selected	O
among	O
probes	O
at	O
gene	O
body	O
,	O
that	O
is	O
,	O
+	O
4	O
kb	O
downstream	O
from	O
the	O
TSS	O
through	O
the	O
transcrip	O
-	O
tion	O
termination	O
site	O
based	O
on	O
a	O
previous	O
report	O
.	O
31	O

TCGA	O
samples	O
and	O
their	O
HPV	O
status	O

Independent	O
Inﬁnium	O
datasets	O
of	O
81	O
OPSCC	O
samples	O
supplied	O
by	O
TCGA	O
were	O
used	O
for	O
additional	O
and	O
combined	O
analysis	O
of	O
DNA	O
methylation	O
status	O
.	O

Their	O
HPV	O
status	O
was	O
determined	O
by	O
either	O
p16	O
-	O
IHC	O
or	O
in	O
situ	O
hybridization	O
test	O
,	O
and	O
adapted	O
to	O
our	O
study	O
.	O

Targeted	O
exon	O
-	O
sequencing	O

Targeted	O
exon	O
-	O
sequencing	O
against	O
86	O
clinical	O
OPSCC	O
and	O
seven	O
noncancerous	O
mucosa	O
samples	B-HPV_Sample_Type
was	O
performed	O
using	O
GeneRead	O
DNAseq	O
Targeted	O
Panels	O
V2	O
and	O
the	O
Human	O
Com	O
-	O
prehensive	O
Cancer	O
Panel	O
(	O
Qiagen	O
)	O
,	O
which	O
targets	O
160	O
candidate	O
driver	O
genes	O
,	O
suits	O
short	O
amplicon	O
design	O
and	O
enables	O
detec	O
-	O
tion	O
of	O
low	O
-	O
level	O
mutations	O
,	O
reducing	O
the	O
amount	O
of	O
DNA	O
required	O
.	O

For	O
each	O
of	O
the	O
somatic	O
mutations	O
identiﬁed	O
using	O
this	O
analysis	O
,	O
variants	O
with	O
an	O
allele	O
frequency	O
<	O
0	O
.	O
1	O
and	O
>	O
0	O
.	O
9	O
were	O
excluded	O
.	O

The	O
known	O
variants	O
previously	O
reported	O
in	O
the	O
dbSNP	O
were	O
ﬁltered	O
out	O
,	O
and	O
synonymous	O
mutations	O
were	O
also	O
excluded	O
.	O

Subsequently	O
,	O
we	O
used	O
MutationTaster	O
classiﬁcation	O
tools	O
that	O
can	O
predict	O
the	O
functional	O
consequences	O
of	O
amino	O
acid	O
changes	O
or	O
frame	O
-	O
shift	O
mutation	O
,	O
and	O
considered	O
the	O
observed	O
mutations	O
signiﬁ	O
-	O
cant	O
when	O
MutationTaster	O
evaluated	O
“disease	O
-	O
causing	O
auto	O
-	O
matically	O
.	O
”	O
Finally	O
,	O
we	O
excluded	O
the	O
mutations	O
that	O
were	O
also	O
found	O
in	O
seven	O
noncancerous	O
samples	B-HPV_Sample_Type
.	O

Mutation	O
signatures	O
analysis	O

De	O
novo	O
extractions	O
of	O
mutation	O
signatures	O
and	O
quantiﬁcation	O
of	O
the	O
contribution	O
of	O
Catalogue	O
of	O
Somatic	O
Mutations	O
in	O
Cancer	O
(	O
COSMIC	O
)	O
signatures	O
to	O
the	O
mutational	O
proﬁles	O
were	O
performed	O
,	O
using	O
R	O
-	O
3	O
.	O
5	O
.	O
1	O
(	O
)	O
,	O
MutationalPatterns	O
(	O
)	O
and	O
NMF	O
packages	O
(	O
)	O
.	O

Figure	O
1	O
.	O

Inﬁnium	O
450k	O
analysis	O
of	O
OPSCC	O
and	O
noncancerous	O
samples	O
from	O
our	O
study	O
and	O
TCGA	O
.	O

(	O
a	O
)	O
HPV	O
infection	O
status	O
.	O

The	O
presence	O
of	O
the	O
HPV	O
-	O
L1	O
region	O
was	O
analyzed	O
using	O
PCR	B-HPV_Lab_Technique
(	I-HPV_Lab_Technique
142	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
bp	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
product	I-HPV_Lab_Technique
)	O
,	O
followed	O
by	O
gel	O
electrophoresis	O
.	O

Most	O
p16	O
(	O
+	O
)	O
cases	O
were	O
HPV	O
-	O
L1	O
(	O
+	O
)	O
(	O
Case	O
1	O
)	O
,	O
whereas	O
p16	O
(	O
−	O
)	O
cases	O
were	O
generally	O
HPV	O
-	O
L1	O
(	O
−	O
)	O
.	O

(	O
b	O
)	O
Immunostaining	O
of	O
p16	O
and	O
p53	O
.	O

Top	O
,	O
hematoxylin	O
and	O
eosin	O
;	O
middle	O
,	O
p16	O
;	O
bottom	O
,	O
p53	O
.	O
p16	O
(	O
+	O
)	O
correlated	O
inversely	O
with	O
TP53	O
-	O
mutation	O
;	O
that	O
is	O
,	O
most	O
p16	O
(	O
+	O
)	O
OPSCC	O
samples	O
showed	O
TP53	O
-	O
mutation	O
(	O
−	O
)	O
status	O
(	O
Case	O
1	O
)	O
.	O

Most	O
p16	O
(	O
−	O
)	O
OPSCC	O
cases	O
showed	O
TP53	O
-	O
mutation	O
(	O
+	O
)	O
,	O
either	O
positive	O
staining	O
of	O
p53	O
(	O
Case	O
2	O
)	O
or	O
negative	O
staining	O
of	O
p53	O
(	O
Case	O
3	O
)	O
.	O

Scale	O
bar	O
,	O
100	O
μm	O
.	O

(	O
c	O
)	O
Genome	O
-	O
wide	O
DNA	O
methylation	O
analyzed	O
for	O
clinical	O
OPSCC	O
(	O
n	O
=	O
89	O
)	O
and	O
noncancerous	O
samples	O
(	O
n	O
=	O
5	O
)	O
.	O

A	O
probe	O
nearest	O
to	O
the	O
transcriptional	O
start	O
site	O
(	O
TSS	O
)	O
was	O
selected	O
for	O
analysis	O
of	O
each	O
promoter	O
region	O
.	O

Probes	O
with	O
standard	O
deviation	O
of	O
β	O
-	O
values	O
>	O
0	O
.	O
10	O
in	O
89	O
clinical	O
OPSCC	O
and	O
ﬁve	O
noncancerous	O
mucosa	O
samples	O
(	O
n	O
=	O
2	O
,	O
404	O
)	O
were	O
used	O
for	O
clustering	O
(	O
top	O
)	O
.	O

Genes	O
with	O
CpG	O
island	O
shore	O
regions	O
upstream	O
(	O
N	O
_	O
Shore	O
)	O
and	O
downstream	O
(	O
S	O
_	O
Shore	O
)	O
from	O
TSS	O
,	O
and	O
gene	O
body	O
regions	O
are	O
also	O
shown	O
(	O
middle	O
)	O
.	O

The	O
methylation	O
data	O
of	O
PBMCs	O
and	O
ﬁbroblasts	O
are	O
additionally	O
shown	O
as	O
the	O
normal	O
control	O
(	O
right	O
)	O
.	O

White	O
:	O
HPV	O
-	O
L1	O
(	O
−	O
)	O
,	O
p16	O
(	O
−	O
)	O
,	O
TP53	O
-	O
mutation	O
(	O
−	O
)	O
and	O
alive	O
.	O

Black	O
:	O
HPV	O
-	O
L1	O
(	O
+	O
)	O
,	O
p16	O
(	O
+	O
)	O
,	O
TP53	O
-	O
mutation	O
(	O
+	O
)	O
and	O
dead	O
.	O

Color	O
codes	O
indicate	O
race	O
(	O
bottom	O
)	O
.	O

(	O
d	O
)	O
Genome	O
-	O
wide	O
DNA	O
methylation	O
analysis	O
for	O
81	O
clinical	O
OPSCC	O
samples	B-HPV_Sample_Type
obtained	O
from	O
TCGA	O
.	O

The	O
same	O
2	O
,	O
404	O
probes	O
were	O
used	O
for	O
clustering	O
(	O
top	O
)	O
.	O

Genes	O
with	O
CpG	O
island	O
shore	O
regions	O
upstream	O
(	O
N	O
_	O
Shore	O
)	O
and	O
downstream	O
(	O
S	O
_	O
Shore	O
)	O
from	O
TSS	O
,	O
and	O
gene	O
body	O
regions	O
are	O
also	O
shown	O
(	O
middle	O
)	O
.	O

[	O
Color	O
ﬁgure	O
can	O
be	O
viewed	O
at	O
]	O

Gene	O
ontology	O
analysis	O

Gene	O
annotation	O
enrichment	O
analysis	O
was	O
conducted	O
based	O
on	O
GO	O
(	O
biological	O
process	O
,	O
cellular	O
component	O
and	O
molecular	O
function	O
)	O
using	O
the	O
Functional	O
Annotation	O
tool	O
of	O
Metascape	O
.	O
32	O

Pyrosequencing	O
analysis	O

Methylation	O
status	O
in	O
77	O
OPSCC	O
cases	O
and	O
two	O
normal	O
sam	B-HPV_Sample_Type
-	I-HPV_Sample_Type
ples	I-HPV_Sample_Type
was	O
quantitatively	O
validated	O
using	O
pyrosequencing	O
with	O
PyroMark	O
Q96	O
(	O
Qiagen	O
)	O
as	O
previously	O
reported	O
.	O
30	O
Primers	O
were	O
designed	O
using	O
the	O
Pyro	O
Q	O
-	O
CpG	O
software	O
(	O
Qiagen	O
)	O
to	O

Figure	O
2	O
.	O

Legend	O
on	O
next	O
page	O
.	O

amplify	O
bisulﬁte	O
-	O
treated	O
DNA	O
(	O
Supporting	O
Information	O
Table	O
S1	O
)	O
.	O

Methylation	O
control	O
samples	B-HPV_Sample_Type
(	O
0	O
,	O
25	O
,	O
50	O
,	O
75	O
and	O
100	O
%	O
)	O
were	O
prepared	O
as	O
described	O
previously33	O
and	O
used	O
to	O
conﬁrm	O
the	O
high	O
quantiﬁcation	O
ability	O
of	O
pyrosequencing	O
assays	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S2	O
)	O
.	O

Statistical	O
analysis	O

Association	O
between	O
clinicopathological	O
factors	O
and	O
DNA	O
methylation	O
or	O
mutation	O
status	O
was	O
analyzed	O
using	O
the	O
Fisher’s	O
exact	O
test	O
,	O
χ2	O
test	O
and	O
Student’s	O
t	O
-	O
test	O
.	O

Unsupervised	O
two	O
-	O
way	O
hierarchical	O
clustering	O
was	O
performed	O
using	O
the	O
Clus	O
-	O
ter	O
3	O
.	O
0	O
software	O
.	O

OS	O
was	O
measured	O
from	O
the	O
date	O
of	O
registra	O
-	O
tion	O
to	O
the	O
date	O
of	O
OPSCC	O
-	O
related	O
death	O
,	O
ﬁltering	O
out	O
patients	O
who	O
were	O
alive	O
at	O
last	O
follow	O
-	O
up	O
and	O
non	O
-	O
OPSCC	O
-	O
related	O
deaths	O
.	O

OS	O
distribution	O
was	O
estimated	O
using	O
the	O
Kaplan–Meier	O
method	O
.	O

Differences	O
between	O
groups	O
were	O
determined	O
using	O
a	O
log	O
-	O
rank	O
test	O
and	O
Cox	O
proportional	O
hazard	O
model	O
using	O
the	O
R	O
software	O
.	O

Univariate	O
and	O
multivariate	O
analysis	O
for	O
correlation	O
of	O
clinicopathological	O
factors	O
with	O
prognosis	O
was	O
performed	O
using	O
the	O
Cox	O
proportional	O
hazard	O
model	O
.	O

p	O
<	O
0	O
.	O
01	O
or	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
signiﬁ	O
-	O
cant	O
.	O

False	O
discovery	O
rate	O
was	O
estimated	O
by	O
calculation	O
of	O
q	O
-	O
value	O
by	O
Benjamini–Hochberg	O
method	O
.	O

Data	O
availability	O

Inﬁnium	O
data	O
were	O
submitted	O
to	O
the	O
GEO	O
database	O
under	O
the	O
accession	O
number	O
GSE124633	O
.	O

Targeted	O
exon	O
-	O
sequencing	O
data	O
were	O
submitted	O
to	O
the	O
Sequence	O
Read	O
Archive	O
(	O
SRA	O
)	O
database	O
under	O
the	O
accession	O
number	O
:	O
SRR8775783−SRR8775850	O
.	O

